EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Secondary Analysis of a Randomized Controlled Trial of Adjuvant Chemotherapy by PSA Response Following Radiotherapy

Stephen Andrew Mihalcik, Meredith M. Regan, Seth A. Rosenthal, Glenn J. Bubley, Kenneth J. Pienta, Leonard G. Gomella, Alan C. Hartford, Jeff M. Michalski, Raghu Rajan, Andrew Michael McDonald, Michael M. Dominello, David Grignon und 5 weitere

Cancer Medicine · 2026-11 · 15 (11)

DOI: 10.1002/cam4.71910 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Cancer Medicine, online erschienen am 18.11.2026. Verfasst von Stephen Andrew Mihalcik und 16 weiteren Autor:innen. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Cancer Institute, Pfizer.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

NRG Oncology RTOG 9902 was a randomized controlled trial of the addition of adjuvant chemotherapy (paclitaxel, oral etoposide, estramustine) to long‐course androgen suppression and radiation for patients with high‐risk prostate cancer. The trial closed early due to excess toxicity and found no benefit to chemotherapy at a median follow‐up of 9.2 years.

Methods

Immediate post‐radiation PSA status was dichotomized at ≤ 0.2 ng/mL. Landmark analysis redefined starting times for disease‐free survival (DFS), time to distant metastasis (TDM), and overall survival (OS) at 36 weeks post‐radiation, when planned chemotherapy was complete. Exclusion criteria included non‐receipt of radiation or assigned chemotherapy and pre‐landmark DFS events or loss to follow‐up. Hazard ratios (HR), 95% confidence intervals, and PSA‐by‐treatment interaction estimated by Cox or competing‐risks regression.

Findings

Of 333 patients analyzed: 190 without and 143 with chemotherapy. Chemotherapy was associated with improved DFS for patients with PSA > 0.2 (HR 0.59, 0.38–0.91), but not for those with PSA ≤ 0.2 (HR 0.94, 0.60–1.46), interaction p = 0.13. There was no association with chemotherapy relative to post‐RT PSA for either TDM or OS.

Interpretation

This analysis suggests that men with a post‐radiation PSA > 0.2 may benefit from treatment intensification with adjuvant chemotherapy. Prospective trials adapting treatment by PSA response are indicated. Trial Registration Trial Number: NCT00004054 ( ClinicalTrials.gov )

Förderung

  • National Cancer Institute
  • Pfizer

Zitieren

APA

Mihalcik, S. A., Regan, M. M., Rosenthal, S. A., Bubley, G. J., Pienta, K. J., Gomella, L. G., Hartford, A. C., Michalski, J. M., Rajan, R., McDonald, A. M., Dominello, M. M., Grignon, D., Jones, C. U., Atkins, J. N., Moughan, J., Sandler, H. M., & Kaplan, I. D. (2026). Secondary Analysis of a Randomized Controlled Trial of Adjuvant Chemotherapy by PSA Response Following Radiotherapy. Cancer Medicine, 15(11). https://doi.org/10.1002/cam4.71910

Vancouver

Mihalcik SA, Regan MM, Rosenthal SA, Bubley GJ, Pienta KJ, Gomella LG, et al. Secondary Analysis of a Randomized Controlled Trial of Adjuvant Chemotherapy by PSA Response Following Radiotherapy. Cancer Medicine. 2026;15(11). doi:10.1002/cam4.71910

BibTeX
@article{Mihalcik2026,
  author = {Mihalcik, Stephen Andrew and Regan, Meredith M. and Rosenthal, Seth A. and Bubley, Glenn J. and Pienta, Kenneth J. and Gomella, Leonard G. and Hartford, Alan C. and Michalski, Jeff M. and Rajan, Raghu and McDonald, Andrew Michael and Dominello, Michael M. and Grignon, David and Jones, Christopher U. and Atkins, James Norman and Moughan, Jennifer and Sandler, Howard M. and Kaplan, Irving D.},
  title = {Secondary Analysis of a Randomized Controlled Trial of Adjuvant Chemotherapy by PSA Response Following Radiotherapy},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {11},
  doi = {10.1002/cam4.71910}
}
Kostenlos starten →